Current Studies

Drug-Resistant Urinary Tract Infection (UTI)

Location(s): Rovia Doral (Universal Axon Site)

A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug-Resistant E. Coli

This study evaluates an investigational treatment called LBP-EC01, which uses bacteriophages (viruses that target bacteria) to treat acute UTIs caused by drug-resistant E. coli. Participants will receive either the study drug or a placebo, both alongside standard antibiotic therapy. The goal is to find a safe and more effective way to treat UTIs when traditional antibiotics may not work.

Eligibility:
• Adults with a recent history of UTIs caused by drug-resistant E. coli
• Currently experiencing an uncomplicated UTI
• Not currently taking antibiotics to treat this infection

Obesity, Type 2 Diabetes

Location(s): Rovia Doral (Universal Axon Site)

A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

This Phase II trial tests the safety and potential benefits of AZD6234 for people with overweight or obesity and Type 2 Diabetes already using a GLP-1 receptor agonist. The goal is to see whether AZD6234 can support better weight and blood sugar control. Participants will continue their current treatment while also receiving the study drug or a placebo.

Eligibility:
• Ages 18–75
• Diagnosed with Type 2 Diabetes
• Currently using a GLP-1 medication and not using insulin

Type 2 Diabetes

Location(s): Rovia Doral (Universal Axon Site)

A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study)

This study explores a new endoscopic procedure to help manage type 2 diabetes in people whose condition isn’t well-controlled with current non-insulin medications. Researchers aim to determine whether this therapy is safe and effective in improving blood sugar levels. Participants must meet specific health criteria and be willing to follow study requirements, including certain medication restrictions and preparation for procedures.

Eligibility:
• Ages 22–70
• Diagnosed with Type 2 Diabetes
• Not currently using insulin

Headquarters
The Pavilion at Doral
3650 NW 82nd Ave, PH 503
Suite 208
Doral, FL 33166

Tel: (305) 677-9267
Fax: (305) 503-9363